A phase I open-label, two period, single center study to assess the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2010
At a glance
- Drugs Nilotinib; Rifampicin
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Malignant melanoma; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 20 Jan 2007 New trial record.